Artículos

Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia / Geartsje Boonstra en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 146-153 Título : Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia Tipo de documento: texto impreso Autores: Geartsje Boonstra, Autor ; Neeltje E. M. van Haren,, Autor ; Hugo G. Schnack, Autor Fecha de publicación: 2022 Artículo en la página: pp. 146-153 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agentes antipsicóticos, Resonancia magnética, Esquizofrenia, Estudios de seguimiento, Suspensión del tratamiento Resumen: The influence of antipsychotic medication on brain morphology in schizophrenia may confound interpretation of brain changes over time. We aimed to assess the effect of discontinuation of atypical antipsychotic medication on change in brain volume in patients. Link: ./index.php?lvl=notice_display&id=29382 [artículo] Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia [texto impreso] / Geartsje Boonstra, Autor ; Neeltje E. M. van Haren,, Autor ; Hugo G. Schnack, Autor . - 2022 . - pp. 146-153. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 146-153 Palabras clave: Agentes antipsicóticos, Resonancia magnética, Esquizofrenia, Estudios de seguimiento, Suspensión del tratamiento Resumen: The influence of antipsychotic medication on brain morphology in schizophrenia may confound interpretation of brain changes over time. We aimed to assess the effect of discontinuation of atypical antipsychotic medication on change in brain volume in patients. Link: ./index.php?lvl=notice_display&id=29382

Metabolic effects of olanzapine in patients with newly diagnosed psychosis / Emilio Fernández Egea en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 154-159 Título : Metabolic effects of olanzapine in patients with newly diagnosed psychosis Tipo de documento: texto impreso Autores: Emilio Fernández Egea, Autor ; Brian J. Miller, Autor ; Clemente Garcia Rizo, Autor Fecha de publicación: 2022 Artículo en la página: pp. 154-159 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Olanzapina, Psicosis, Diabetes, Antecedentes familiares Resumen: Antipsychotic medications are associated with an increased risk of diabetes. Previous studies have also found an increased risk of type 2 diabetes mellitus in the relatives of schizophrenia probands. The aim of this study was to explore the metabolic adverse effects of olanzapine in a cohort of patients with newly diagnosed psychosis and minimal or no exposure to antipsychotics. Link: ./index.php?lvl=notice_display&id=29383 [artículo] Metabolic effects of olanzapine in patients with newly diagnosed psychosis [texto impreso] / Emilio Fernández Egea, Autor ; Brian J. Miller, Autor ; Clemente Garcia Rizo, Autor . - 2022 . - pp. 154-159. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 154-159 Palabras clave: Olanzapina, Psicosis, Diabetes, Antecedentes familiares Resumen: Antipsychotic medications are associated with an increased risk of diabetes. Previous studies have also found an increased risk of type 2 diabetes mellitus in the relatives of schizophrenia probands. The aim of this study was to explore the metabolic adverse effects of olanzapine in a cohort of patients with newly diagnosed psychosis and minimal or no exposure to antipsychotics. Link: ./index.php?lvl=notice_display&id=29383

A randomized, double blind, parallel-group, fixed dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment resistant schizophrenia or schizoaffective disorder / Jean-Pierre Lindenmayer en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 160-168 Título : A randomized, double blind, parallel-group, fixed dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment resistant schizophrenia or schizoaffective disorder Tipo de documento: texto impreso Autores: Jean-Pierre Lindenmayer, Autor ; Leslie L. Citrome, Autor ; Anzalee Khan, Autor Fecha de publicación: 2022 Artículo en la página: pp. 160-168 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Dosis altas de quetiapina, Esquizofrenia resistente al tratamiento Resumen: Quetiapine is often prescribed at doses higher than those approved by regulatory authorities, with limited evidence from controlled trials. The objective of this study was to assess the safety, tolerability, and efficacy of high-dose quetiapine (1200 mg/d) compared with a standard dose of 600 mg/d among patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, schizophrenia or schizoaffective disorder hospitalized at 2 state-operated psychiatric facilities. Link: ./index.php?lvl=notice_display&id=29384 [artículo] A randomized, double blind, parallel-group, fixed dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment resistant schizophrenia or schizoaffective disorder [texto impreso] / Jean-Pierre Lindenmayer, Autor ; Leslie L. Citrome, Autor ; Anzalee Khan, Autor . - 2022 . - pp. 160-168. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 160-168 Palabras clave: Dosis altas de quetiapina, Esquizofrenia resistente al tratamiento Resumen: Quetiapine is often prescribed at doses higher than those approved by regulatory authorities, with limited evidence from controlled trials. The objective of this study was to assess the safety, tolerability, and efficacy of high-dose quetiapine (1200 mg/d) compared with a standard dose of 600 mg/d among patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, schizophrenia or schizoaffective disorder hospitalized at 2 state-operated psychiatric facilities. Link: ./index.php?lvl=notice_display&id=29384

Does switching to another antipsychotic in patients with clozapine associated granulocytopenia solve the problem? / Behçet Coşar en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 169-173 Título : Does switching to another antipsychotic in patients with clozapine associated granulocytopenia solve the problem? : Case series of 18 patients Tipo de documento: texto impreso Autores: Behçet Coşar, Autor ; Mustafa Ender Taner, Autor ; Hale Yapc Eser, Autor Fecha de publicación: 2022 Artículo en la página: pp. 169-173 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Clozapina, Agranulocitosis, Prolongación, Esquizofrenia, Olanzapina, Qetiapina, Antipsicótico Resumen: Clozapine is a well-known drug that is used in treatment-resistant schizophrenia, but granulocytopenia, which may lead to a potentially fatal condition such as agranulocytosis, limit its use. The question about which antipsychotic should be used after a diagnosis of clozapine-associated granulocytopenia is difficult to answer, because antipsychotics other than clozapine may also have hematologic toxicity, or they may prolong clozapine-associated granulocytopenia. Link: ./index.php?lvl=notice_display&id=29385 [artículo] Does switching to another antipsychotic in patients with clozapine associated granulocytopenia solve the problem? : Case series of 18 patients [texto impreso] / Behçet Coşar, Autor ; Mustafa Ender Taner, Autor ; Hale Yapc Eser, Autor . - 2022 . - pp. 169-173. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 169-173 Palabras clave: Clozapina, Agranulocitosis, Prolongación, Esquizofrenia, Olanzapina, Qetiapina, Antipsicótico Resumen: Clozapine is a well-known drug that is used in treatment-resistant schizophrenia, but granulocytopenia, which may lead to a potentially fatal condition such as agranulocytosis, limit its use. The question about which antipsychotic should be used after a diagnosis of clozapine-associated granulocytopenia is difficult to answer, because antipsychotics other than clozapine may also have hematologic toxicity, or they may prolong clozapine-associated granulocytopenia. Link: ./index.php?lvl=notice_display&id=29385

Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment resistant obsessive compulsive disorder / Maria Rosaria A. Muscatello en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 174-179 Título : Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment resistant obsessive compulsive disorder : A double blind, placebo controlled study Tipo de documento: texto impreso Autores: Maria Rosaria A. Muscatello, Autor ; Antonio Bruno, Autor ; Gianluca Pandolfo, Autor Fecha de publicación: 2022 Artículo en la página: pp. 174-179 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Aripiprazol, Inhibidores de la recaptación de serotonina, Clomipramina, Trastorno obsesivo-compulsivo Resumen: Based on the evidence that aripiprazole added to serotonin reuptake inhibitors (SRIs) or clomipramine in treatment-resistant obsessive-compulsive disorder (OCD) has reported promising results, the present 16-week, double-blind, randomized, placebo-controlled trial had the aim to explore the efficacy of aripiprazole add-on pharmacotherapy on clinical symptoms and cognitive functioning in a sample of treatment-resistant OCD patients receiving SRIs. Link: ./index.php?lvl=notice_display&id=29386 [artículo] Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment resistant obsessive compulsive disorder : A double blind, placebo controlled study [texto impreso] / Maria Rosaria A. Muscatello, Autor ; Antonio Bruno, Autor ; Gianluca Pandolfo, Autor . - 2022 . - pp. 174-179. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 174-179 Palabras clave: Aripiprazol, Inhibidores de la recaptación de serotonina, Clomipramina, Trastorno obsesivo-compulsivo Resumen: Based on the evidence that aripiprazole added to serotonin reuptake inhibitors (SRIs) or clomipramine in treatment-resistant obsessive-compulsive disorder (OCD) has reported promising results, the present 16-week, double-blind, randomized, placebo-controlled trial had the aim to explore the efficacy of aripiprazole add-on pharmacotherapy on clinical symptoms and cognitive functioning in a sample of treatment-resistant OCD patients receiving SRIs. Link: ./index.php?lvl=notice_display&id=29386

Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication / Shawn M. McClintock en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 180-186 Título : Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication Tipo de documento: texto impreso Autores: Shawn M. McClintock, Autor ; Mustafa M. Husain, Autor ; Stephen R. Wisniewski, Autor Fecha de publicación: 2022 Artículo en la página: pp. 180-186 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Depresión, STAR*D, Residual, Síntomas, Respuesta al tratamiento Nota de contenido: Little is known about the quantity or quality of residual depressive symptoms in patients with major depressive disorder (MDD) who have responded but not remitted with antidepressant treatment. Link: ./index.php?lvl=notice_display&id=29387 [artículo] Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication [texto impreso] / Shawn M. McClintock, Autor ; Mustafa M. Husain, Autor ; Stephen R. Wisniewski, Autor . - 2022 . - pp. 180-186. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 180-186 Palabras clave: Depresión, STAR*D, Residual, Síntomas, Respuesta al tratamiento Nota de contenido: Little is known about the quantity or quality of residual depressive symptoms in patients with major depressive disorder (MDD) who have responded but not remitted with antidepressant treatment. Link: ./index.php?lvl=notice_display&id=29387

Early prediction of fluoxetine response for han chinese inpatients with major depressive disorder / Ching Hua Lin en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 187-193 Título : Early prediction of fluoxetine response for han chinese inpatients with major depressive disorder Tipo de documento: texto impreso Autores: Ching Hua Lin, Autor ; Hsien Yuan Lane, Autor ; Cheng Chung Chen, Autor Fecha de publicación: 2022 Artículo en la página: pp. 187-193 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno depresivo mayor, Fluoxetina, Modelo de predicción temprana Resumen: The onset of antidepressant action is vital clinically. This study aimed to testify whether early symptom improvement can predict eventual treatment response at week 6 among depressive hospitalized patients taking fluoxetine. One hundred thirty-one hospitalized patients with major depressive disorder received 20 mg/d of fluoxetine for 6 weeks. Link: ./index.php?lvl=notice_display&id=29395 [artículo] Early prediction of fluoxetine response for han chinese inpatients with major depressive disorder [texto impreso] / Ching Hua Lin, Autor ; Hsien Yuan Lane, Autor ; Cheng Chung Chen, Autor . - 2022 . - pp. 187-193. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 187-193 Palabras clave: Trastorno depresivo mayor, Fluoxetina, Modelo de predicción temprana Resumen: The onset of antidepressant action is vital clinically. This study aimed to testify whether early symptom improvement can predict eventual treatment response at week 6 among depressive hospitalized patients taking fluoxetine. One hundred thirty-one hospitalized patients with major depressive disorder received 20 mg/d of fluoxetine for 6 weeks. Link: ./index.php?lvl=notice_display&id=29395

What can we learn from chinese randomized controlled trials? A systematic review and meta-analysis of chinese venlafaxine studies / Markus Koesters en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 194-200 Título : What can we learn from chinese randomized controlled trials? A systematic review and meta-analysis of chinese venlafaxine studies Tipo de documento: texto impreso Autores: Markus Koesters, Autor ; Ying Zhang, Autor ; Yong Ma. Chun, Autor Fecha de publicación: 2022 Artículo en la página: pp. 194-200 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Depresión, Venlafaxina, Metanálisis, Estudios chinos, China Resumen: This systematic review evaluated Chinese trials examining the efficacy of venlafaxine in the treatment of depression. Link: ./index.php?lvl=notice_display&id=29396 [artículo] What can we learn from chinese randomized controlled trials? A systematic review and meta-analysis of chinese venlafaxine studies [texto impreso] / Markus Koesters, Autor ; Ying Zhang, Autor ; Yong Ma. Chun, Autor . - 2022 . - pp. 194-200. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 194-200 Palabras clave: Depresión, Venlafaxina, Metanálisis, Estudios chinos, China Resumen: This systematic review evaluated Chinese trials examining the efficacy of venlafaxine in the treatment of depression. Link: ./index.php?lvl=notice_display&id=29396

Meta regression analysis of paroxetine clinical trial data / Marianne Klemp en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 201-206 Título : Meta regression analysis of paroxetine clinical trial data : Does reporting scale matter? Tipo de documento: texto impreso Autores: Marianne Klemp, Autor ; Ingunn Fride Tvete, Autor ; Jørund Inge Gåsemyr, Autor Fecha de publicación: 2022 Artículo en la página: pp. 201-206 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Análisis de metarregresión, Paroxetina, Regresión a la media Resumen: It is unknown to which degree the effect of antidepressant drugs are related to baseline degree of depression, dose level, patient's age, or type of questionnaire used. We explored this for paroxetine. Link: ./index.php?lvl=notice_display&id=29397 [artículo] Meta regression analysis of paroxetine clinical trial data : Does reporting scale matter? [texto impreso] / Marianne Klemp, Autor ; Ingunn Fride Tvete, Autor ; Jørund Inge Gåsemyr, Autor . - 2022 . - pp. 201-206. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 201-206 Palabras clave: Antipsicóticos, Análisis de metarregresión, Paroxetina, Regresión a la media Resumen: It is unknown to which degree the effect of antidepressant drugs are related to baseline degree of depression, dose level, patient's age, or type of questionnaire used. We explored this for paroxetine. Link: ./index.php?lvl=notice_display&id=29397

Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy / Wei Jiang en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 207-213 Título : Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy Tipo de documento: texto impreso Autores: Wei Jiang, Autor ; Shelby Ladd, Autor ; Carolyn Martsberger, Autor Fecha de publicación: 2022 Artículo en la página: pp. 207-213 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Variabilidad de la frecuencia cardíaca, Neuropatía diabética, Pregabalina Resumen: Many studies have demonstrated that low heart rate variability (HRV) is a risk for high mortality and morbidity in patients with cardiovascular diseases. The primary purpose of the study was to evaluate whether pregabalin improves HRV in patients with diabetes and painful peripheral neuropathy. Link: ./index.php?lvl=notice_display&id=29398 [artículo] Effects of pregabalin on heart rate variability in patients with painful diabetic neuropathy [texto impreso] / Wei Jiang, Autor ; Shelby Ladd, Autor ; Carolyn Martsberger, Autor . - 2022 . - pp. 207-213. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 207-213 Palabras clave: Variabilidad de la frecuencia cardíaca, Neuropatía diabética, Pregabalina Resumen: Many studies have demonstrated that low heart rate variability (HRV) is a risk for high mortality and morbidity in patients with cardiovascular diseases. The primary purpose of the study was to evaluate whether pregabalin improves HRV in patients with diabetes and painful peripheral neuropathy. Link: ./index.php?lvl=notice_display&id=29398

Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion / Tanja Veselinović en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 214-220 Título : Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion Tipo de documento: texto impreso Autores: Tanja Veselinović, Autor ; Holger Schorn, Autor ; Ingo B. Vernaleken, Autor Fecha de publicación: 2022 Artículo en la página: pp. 214-220 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Prolactina, Hiperprolactinemia, Antipsicóticos, Reserpina, Aripiprazol Resumen: Antipsychotics are the most common cause of pharmacologically induced hyperprolactinemia. Although this adverse effect was the subject of numerous observations, the mechanisms and promotive factors were not completely investigated yet. Increased awareness of clinical consequences of hyperprolactinemia implicates the necessity for further examinations. Link: ./index.php?lvl=notice_display&id=29399 [artículo] Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion [texto impreso] / Tanja Veselinović, Autor ; Holger Schorn, Autor ; Ingo B. Vernaleken, Autor . - 2022 . - pp. 214-220. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 214-220 Palabras clave: Prolactina, Hiperprolactinemia, Antipsicóticos, Reserpina, Aripiprazol Resumen: Antipsychotics are the most common cause of pharmacologically induced hyperprolactinemia. Although this adverse effect was the subject of numerous observations, the mechanisms and promotive factors were not completely investigated yet. Increased awareness of clinical consequences of hyperprolactinemia implicates the necessity for further examinations. Link: ./index.php?lvl=notice_display&id=29399